MAPS - Abramowitz, Matthew
-
Investigator:
Matthew Abramowitz
Email
Coordinator: Pavel Noa Hechavarria
3052431036
IRB: 20101056
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Prostate
Sponsor: SCCC
Enrolling Sites:
Deerfield
Gables
SylvesterTitle: A Phase II Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial
Eligibility Criteria - NCT01411345 *This information has been extracted from " www.clinicaltrials.gov"
HEAT - Abramowitz, Matthew
-
Investigator:
Matthew Abramowitz
Email
Coordinator: Milad Al Troudy El Troudi
IRB: 20110491
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Prostate
Sponsor: PROSTATE CANCER FOUNDATION
Enrolling Sites:
Deerfield
Gables
Northern Sydney Local Health District
Sylvester
University Hospital Trust of TurinTitle: A Randomized Study of Radiation Hypofractionation via Extended versus Accelerated Therapy (HEAT) For Prostate Cancer
Eligibility Criteria - NCT01794403 *This information has been extracted from " www.clinicaltrials.gov"
20200863 - Abramowitz Matthew
-
Investigator:
Matthew Abramowitz
Email
Coordinator: Pavel Noa Hechavarria
3052431036
IRB: 20200863
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Prostate
Sponsor: Johns Hopkins University
Enrolling Sites:
Deerfield
Gables
SylvesterTitle: A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)
Eligibility Criteria - NCT04037358 *This information has been extracted from " www.clinicaltrials.gov"
20201533 - Benedetto Pasquale
-
Investigator:
Pasquale Benedetto
Email
Coordinator: Ray Lewis
+1 (305) 2434033
IRB: 20201533
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Kidney
Sponsor: Alliance for Clinical Trials in Oncology
Enrolling Sites:
Deerfield
Gables
Kendall
Plantation
SylvesterTitle: PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE] A031704
Eligibility Criteria - NCT03793166 *This information has been extracted from " www.clinicaltrials.gov"
20211217 - Bilusic Marijo
-
Investigator:
Marijo Bilusic
Email
Coordinator:
IRB: 20211217
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Prostate
Sponsor: Surface Oncology
Enrolling Sites:
Sylvester
Title: A Phase 2 Trial of SRF617 in Combination With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration-Resistant Prostate Cancer.
20220121 - Bilusic Marijo
-
Investigator:
Marijo Bilusic
Email
Coordinator: Nailet Real Bestard
+1 (305) 2438173
IRB: 20220121
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Prostate
Sponsor: MERCK SHARP & DOHME
Enrolling Sites:
Sylvester
Title: Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
Eligibility Criteria - NCT02861573 *This information has been extracted from " www.clinicaltrials.gov"
TAPUR - Calfa, Carmen
-
Investigator:
Carmen Calfa
Email
Coordinator: Carolina Troche
+1 (305) 2431481
IRB: 20170529
SDG: Breast Cancer
Disease Site(s): Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue
Sponsor: ASCO
Enrolling Sites:
Aventura
Deerfield
Gables
Kendall
Plantation
SylvesterTitle: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"
20200056 - D'Amato Gina
-
Investigator:
Gina D'Amato
Email
Coordinator: Nailet Real Bestard
+1 (305) 2438173
IRB: 20200056
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Anus,Bladder,Bones and Joints,Breast,Cervix Uteri,Colon,Esophagus,Kidney,Lip, Oral Cavity and Pharynx,Liver,Lung,Melanoma, skin,Other Digestive Organ,Other Urinary,Ovary,Prostate,Rectum,Small Intestine,Soft Tissue,Stomach,Thyroid
Sponsor: DECIPHERA
Enrolling Sites:
Sylvester
Title: A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor
Eligibility Criteria - NCT03069469 *This information has been extracted from " www.clinicaltrials.gov"
20170004 - Gonzalgo Mark
-
Investigator:
Mark Gonzalgo
Email
Coordinator:
IRB: 20170004
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Bladder
Sponsor: SCCC
Enrolling Sites:
Sylvester
UMHTitle: Randomized Clinical Trial of Intra-corporal vs Extra-corporal Urinary Diversion after Robot Assisted Radical Cystectomy
Eligibility Criteria - NCT03469362 *This information has been extracted from " www.clinicaltrials.gov"
QUILTT-3.032 - Gonzalgo, Mark
-
Investigator:
Mark Gonzalgo
Email
Coordinator:
IRB: 20170350
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Bladder
Sponsor: ALTOR BIOSCIENCE CORP
Enrolling Sites:
Sylvester
UMHTitle: CA-ALT-803-01-16: QUILT-3.032 - A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
Eligibility Criteria - NCT03022825 *This information has been extracted from " www.clinicaltrials.gov"
MATCH - Huang, Marilyn
-
Investigator:
Marilyn Huang
Email
Coordinator: Carolina Troche
+1 (305) 2431481
IRB: 20150671
SDG: Gynecologic Cancer
Disease Site(s): Cervix Uteri,Colon,Corpus Uteri,Kaposis sarcoma,Kidney,Larynx,Liver,Multiple Myeloma,Non-Hodgkin Lymphoma,Other Female Genital,Ovary,Pancreas,Prostate,Soft Tissue
Sponsor: ECOG
Enrolling Sites:
Coral Springs
Deerfield
Gables
Hollywood
Kendall
Plantation
SylvesterTitle: Molecular Analysis for Therapy Choice (MATCH)
Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"
20200017 - Libardi Dal Pra Alan
-
Investigator:
Alan Libardi Dal Pra
Email
Coordinator:
IRB: 20200017
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Prostate
Sponsor: SCCC
Enrolling Sites:
Gables
JMH
SylvesterTitle: A Pilot Study Using a Digital Behavioral Intervention with a Smart Water Bottle to Improve Bladder Filling Compliance in Prostate Cancer Patients Undergoing Radiation Therapy
Eligibility Criteria - NCT04946214 *This information has been extracted from " www.clinicaltrials.gov"
CPI-006-001 - Merchan, Jaime
-
Investigator:
Jaime Merchan
Email
Coordinator: Rakhi Modak
+1 (305) 2437387
IRB: 20180279
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Bladder,Bones and Joints,Cervix Uteri,Colon,Corpus Uteri,Kidney,Lip, Oral Cavity and Pharynx,Lung,Lymphoid Leukemia,Non-Hodgkin Lymphoma,Pancreas,Prostate,Rectum,Soft Tissue
Sponsor: CP
Enrolling Sites:
Sylvester
Title: CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers
Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"
PT2977-201 - Merchan, Jaime
-
Investigator:
Jaime Merchan
Email
Coordinator:
IRB: 20180954
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Kidney
Sponsor: Peloton
Enrolling Sites:
Sylvester
Title: PT2977-201 : A Phase 2 Trial of PT2977 in Combination With Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Eligibility Criteria - NCT03634540 *This information has been extracted from " www.clinicaltrials.gov"
RTX-240-01 - Merchan, Jaime
-
Investigator:
Jaime Merchan
Email
Coordinator: Isabel Fernandez
+1 (305) 2435486
IRB: 20200686
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Multiple
Sponsor: Rubius Therapeutics
Enrolling Sites:
Sylvester
Title: PHASE 1/2 STUDY OF RTX-240 AS A MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB
Eligibility Criteria - NCT04372706 *This information has been extracted from " www.clinicaltrials.gov"
20170656 - Penedo Frank
-
Investigator:
Frank Penedo
Email
Coordinator:
IRB: 20170656
SDG: Population Sciences
Disease Site(s): Prostate
Sponsor: SCCC
Enrolling Sites:
Community Clinics
Deerfield
Gables
Hollywood
Kendall
NorthWestern University
Plantation
SylvesterTitle: Culturally Adapted Cognitive Behavioral Stress and Self-Management (C-CBSM) Intervention for Prostate Cancer
Eligibility Criteria - NCT03344757 *This information has been extracted from " www.clinicaltrials.gov"
Tbio-6517-ITu-001 - Pimentel, Agustin
-
Investigator:
Agustin Pimentel
Email
Coordinator: Rakhi Modak
+1 (305) 2437387
IRB: 20200277
SDG: Colorectal Cancer
Disease Site(s): Multiple
Sponsor: TSB
Enrolling Sites:
Sylvester
Title: A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination with Pembrolizumab, in Patients with Advanced Solid Tumors
Eligibility Criteria - NCT04301011 *This information has been extracted from " www.clinicaltrials.gov"
The Miami BLaStM Trial - Pollack, Alan
-
Investigator:
Alan Pollack
Email
Coordinator: Pavel Noa Hechavarria
3052431036
IRB: 20140627
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Prostate
Sponsor: SCCC
Enrolling Sites:
Deerfield
Gables
JMH
SylvesterTitle: A Phase II Randomized Trial of MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy ? The Miami BLaStM Trial
Eligibility Criteria - NCT02307058 *This information has been extracted from " www.clinicaltrials.gov"
COMPPARE - Pollack, Alan
-
Investigator:
Alan Pollack
Email
Coordinator:
IRB: 20190275
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Prostate
Sponsor: PCORI
Enrolling Sites:
Deerfield
Gables
SylvesterTitle: COMPPARE: ?A Prospective COMparative Study of Outcomes with Proton and Photon RAdiation in Prostate CancEr.
Eligibility Criteria - NCT03561220 *This information has been extracted from " www.clinicaltrials.gov"
SWOG S1802 - Ritch, Chad
-
Investigator:
Chad Ritch
Email
Coordinator:
IRB: 20180970
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Prostate
Sponsor: SWOG
Enrolling Sites:
Deerfield
Gables
SylvesterTitle: S1802: PHASE III RANDOMIZED TRIAL OF STANDARD SYSTEMIC THERAPY (SST) VERSUS STANDARD SYSTEMIC THERAPY PLUS DEFINITIVE TREATMENT (SURGERY OR RADIATION) OF THE PRIMARY TUMOR IN METASTATIC PROSTATE CANCER
Eligibility Criteria - NCT03678025 *This information has been extracted from " www.clinicaltrials.gov"
20220331 - Ritch Chad
-
Investigator:
Chad Ritch
Email
Coordinator:
IRB: 20220331
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Bladder,Other Male Genital
Sponsor: ECOG
Enrolling Sites:
Sylvester
Title: EA8134: InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative study)
RPL-001-16 - Rodriguez, Estelamari
-
Investigator:
Estelamari Rodriguez
Email
Coordinator: Yanel Diaz Caro
3052438227
IRB: 20180802
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Bladder,Breast-Female,Colon,Melanoma, skin
Sponsor: REPLIMUNE
Enrolling Sites:
Sylvester
Title: RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
Eligibility Criteria - NCT03767348 *This information has been extracted from " www.clinicaltrials.gov"
DST-2970 - Sharma, Janaki
-
Investigator:
Janaki Sharma
Email
Coordinator: Isabel Fernandez
+1 (305) 2435486
IRB: 20200540
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Prostate
Sponsor: DISPERSOL TECH
Enrolling Sites:
Sylvester
Title: A Phase 1 PK and Dose Escalation and Expansion Study of DST-2970 in Patients With Prostate Cancer With Rising PSA on Treatment With Abiraterone Acetate
Eligibility Criteria - NCT04291664 *This information has been extracted from " www.clinicaltrials.gov"
SPN-00714 - Valdes, Frances
-
Investigator:
Frances Valdes
Email
Coordinator: Yanel Diaz Caro
3052438227
IRB: 20190673
SDG: Other
Disease Site(s): Breast,Colon,Esophagus,Kidney,Lung,Other Female Genital,Ovary,Stomach
Sponsor: MTEM
Enrolling Sites:
Sylvester
Title: A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors
Eligibility Criteria - NCT04029922 *This information has been extracted from " www.clinicaltrials.gov"